A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AOEs / arterial occlusive events

[Related PubMed/MEDLINE]
Total Number of Papers: 9
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AOEs  (>> Co-occurring Abbreviation)
Long Form:   arterial occlusive events
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. ALL, CML, TKIs
2021 Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. CML, LDL, SCORE
2021 Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. CP-CML, TKIs
2020 Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report. ---
2020 Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. ACEi, ARBs, CML, CV, RAS, TKIs
2019 Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. CML, SCORE
2019 Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. CML
2018 Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. ALL, CML, CP-CML, MCyR, MMR, PACE
2017 Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. AE, CML, CP-CML, MaHR, MCyR, TKI